Clinical trials: Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
- Condition Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
- Funder type Industry (pharma, biotech, devices)
Schizophrenia
Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)
This 3-part dose titration study will assess elpipodect safety, tolerability, pharmacokinetics (PK), and central nervous system activity.
- Trial name
- NCT02181803
- Testing
- Elpipodect, Base Monotherapy
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants
The purpose of this study is to evaluate the effectiveness and safety of paliperidone extended release (ER) treatment in Thai schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality…
- Trial name
- PRESENT (NCT01387542)
- Testing
- Paliperidone extended release (ER)
- Where
- 2 sites in Thailand
- Volunteers
- 40 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Schizophrenia
Study of SPG302 in Adults With Schizophrenia
This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.
- Trial name
- NCT06442462
- Testing
- SPG302
- Where
- 3 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Spinogenix
Schizophrenic Disorders
Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
The purpose of this study is to develop the weight management program, which is combined with healthy diet, proper physical exercise, and behavior modification, related to patient's quality of life.
- Trial name
- NCT00485823
- Testing
- Olanzapine Hydrochloride, Weight Management Program
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Bipolar 1 Disorder, Schizophrenia
Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia
The purpose of this study is to evaluate the pharmacokinetics of aripiprazole in subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal aderence and are currently on treatment with oral aripiprazole.
- Conditions
- Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Disorders
- Trial name
- NCT02050854
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia
- Trial name
- NCT01009060
- Testing
- GSK239512
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Acute Agitation
Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INP105, which is an investigational drug-device combination product comprised of the drug component OLZ administered by a…
- Trial name
- SNAP101 (NCT03624322)
- Testing
- Zyprexa IM, Zydis, INP105
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Impel Pharmaceuticals
Bipolar I Disorder, Schizophrenia
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
To evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with schizophrenia or Bipolar I disorder
- Trial name
- NCT04987229
- Testing
- OLZ/SAM
- Where
- 35 sites in United States, Argentina and 3 more
- Volunteers
- 236 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia
This Study is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Fixed-Dose, Phase 3 Clinical Trial Evaluating the Efficacy and Safety of WID-RGC20 3 mg/day and 6 mg/day in Patients with Acute Psychotic…
- Trial name
- NCT05168007
- Testing
- WID-RGC20(Cariprazine) 3mg/day, WID-RGC20(Cariprazine) 6mg/day
- Where
- South Korea
- Volunteers
- 342 people
- Sponsor
- Whanin Pharmaceutical Company
Schizophrenia
Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers
The purpose of this study is to compare the rate and extent of absorption of Aripiprazole Oral Soluble Film 10 mg (Test) versus Abilify® 10 mg tablet (Reference) in healthy male volunteers
- Trial name
- NCT02501109
- Testing
- Aripiprazole
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- CMG Pharmaceutical Co. Ltd
Schizophrenia
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
The objective of this study is to investigate the safety and efficacy of aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over a period of 52 weeks in subjects who…
- Trial name
- NCT01942148
- Testing
- Aripiprazole
- Where
- 8 sites in Japan
- Volunteers
- 68 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users
This study uses existing health records and insurance claims data to understand how adults in the United States are treated with KarXT, a medication for schizophrenia.
- Trial name
- NCT07571148
- Testing
- KarXT (xanomeline and trospium)
- Where
- United States
- Volunteers
- 6,876 people
- Sponsor
- Bristol-Myers Squibb
Schizophrenia
A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.
- Trial name
- NCT04712734
- Testing
- Iloperidone
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)
The primary objective of this study is to determine if Australian patients with schizophrenia treated with paliperidone palmitate under conditions of continuous monitoring of outcomes over a 12-month period achieve relapse rates…
- Trial name
- NCT01362426
- Testing
- paliperidone palmitate
- Where
- 10 sites in Australia
- Volunteers
- 127 people
- Sponsor
- Janssen-Cilag Pty Ltd
Schizophrenia
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
The primary objective of this study is to evaluate the long term safety and tolerability of ALKS 3831 in subjects with schizophrenia.
- Trial name
- NCT02669758
- Testing
- ALKS 3831
- Where
- 31 sites in United States, Bulgaria and 2 more
- Volunteers
- 281 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients
This study is a 12-week, double-blind, placebo-controlled trial of L-methylfolate 15 mg/d supplementation in schizophrenia patients with mild or greater negative symptoms.
- Trial name
- NCT01091506
- Testing
- L-methylfolate
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Pamlab, Inc.
Schizophrenia
Comparison of the Effectiveness of Brexpiprazole With That of Risperidone
To demonstrate that the effectiveness of brexpiprazole (2-4 mg/day) on quality of life is non-inferior to that of risperidone (4-6 mg/day) in adult patients with schizophrenia.
- Trial name
- TAILWIND (NCT02758067)
- Testing
- brexpiprazole, risperidone
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Psychotic Disorders
Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone
To assess the effect of risperidone 2 mg daily (QD) on the differential sensitivity of 2 spatial working memory tests (the GMLT and MDR) in non-agitated, drug-naive patients suffering from first-episode…
- Trial name
- NCT00174200
- Testing
- Risperidone 2 mg
- Where
- 3 sites in Canada, Russia
- Volunteers
- 20 people
- Sponsor
- Pfizer
Schizophrenia, Schizoaffective Disorder
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT05859698
- Testing
- Valbenazine
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia, Schizoaffective Disorder
Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
The purposes of this study are to assess the efficacy, safety, and side effects among doses approved by the Food and Drug Administration and higher (not FDA approved) doses of olanzapine in patients with schizophrenia or…
- Trial name
- NCT00100776
- Testing
- Olanzapine
- Where
- 33 sites in United States
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.